Table 6.
Treatment results in the five consecutive periods.
| Protocol | AML-PPLLSG 83 N = 187 |
AML-PPLLSG 94 N = 74 |
AML-PPLLSG 98 N = 151 |
AML-BFM 2004 Interim N = 356 |
AML-BFM 2012 Registry N = 131 |
|---|---|---|---|---|---|
| Complete morphological remission—CR (%) | 133 (71) | 49 (66) | 127 (84) | 310 (87) | 114 (87) |
| Non-responders (%) | 9 (5) | 15 (20) | 16 (11) | 25 (7) | 9 (7) |
| Early deaths (<42 days) (%) | 45 (24) | 10 (14) | 8 (5) | 21 (6) | 8 (6) |
| Deaths in remission (%) | 21 (11) | 9 (12) | 14 (9) | 18 (5) | 2 (1.5) |
| Relapses (%) | 54 (29) | 17 (23) | 50 (33) | 110 (31) | 22 (17) |
| Continuous remission (%) | 58 (31) | 23 (31) | 63 (42) | 182 (51) | 90 (69) |
| Probability of 3-years/5-years OS ± SD |
0.34 ± 0.03/ 0.31 ± 0.03 |
0.37 ± 0.05/ 0.37 ± 0.05 |
0.54 ± 0.04/ 0.52 ± 0.04 |
0.67 ± 0.03/ 0.64 ± 0.03 |
0.75 ± 0.05/nd |
| Probability of 3-years/5-years EFS ± SD |
0.31 ± 0.03/ 0.30 ± 0.03 |
0.34 ± 0.05/ 0.33 ± 0.05 |
0.44 ± 0.04/ 0.42 ± 0.04 |
0.53 ± 0.03/ 0.51 ± 0.03 |
0.67 ± 0.05/nd |
| Probability of 3-years/5-years RFS ± SD |
0.52 ± 0.03/ 0.51 ± 0.03 |
0.65 ± 0.05/ 0.62 ± 0.05 |
0.58 ± 0.04/ 0.56 ± 0.04 |
0.66 ± 0.03/ 0.63 ± 0.03 |
0.78 ± 0.05/nd |
nd—no data (because of the short follow-up in the last period (protocol AML-BFM 2012 Registry), only the probabilities of three-year survival were assessed). OS—overall survival; EFS—event-free survival; RFS—relapse free survival; SD—standard deviation.